Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06726148 · ClinicalTrials.gov registry record · Phase 1
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
A Phase 1 study of Advanced HR+/HER2- Breast Cancer and Advanced CCNE1-amplified Solid Tumors, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 280
- Enrollment target
- 20
- Study locations
NCT06726148 is a Phase 1 study of Advanced HR+/HER2- Breast Cancer and Advanced CCNE1-amplified Solid Tumors that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 280 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT06726148, a Phase 1 study of Advanced HR+/HER2- Breast Cancer and Advanced CCNE1-amplified Solid Tumors, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 280 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.
Conditions Studied
Interventions
- DRUG ribociclib
- DRUG fulvestrant
- DRUG ECI830
Study Locations (20)
Other
- Novartis Investigative Site - Brno
- Novartis Investigative Site - Copenhagen
- Novartis Investigative Site - Odense C
- Novartis Investigative Site - Bordeaux
- Novartis Investigative Site - Saint-Herblain
- Novartis Investigative Site - Heidelberg
- Novartis Investigative Site - Ulm
Victoria
- Novartis Investigative Site - Clayton
- Novartis Investigative Site - Melbourne
California
- University of California LA - Los Angeles
Florida
- Florida Cancer Specialists - Fort Myers
Massachusetts
- Dana Farber Cancer Institute - Boston
Missouri
- WA Uni School Of Med - St Louis
New York
- Memorial Sloan Kettering - New York
Tennessee
- SCRI Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2025-04-03 |
| Est. Completion | 2028-09-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06726148
The ClinicalTrials.gov registry entry for NCT06726148 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced HR+/HER2- Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which ribociclib is the first listed.
NCT06726148 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Victoria, California.
Frequently Asked Questions
What is clinical trial NCT06726148 about?
NCT06726148 is a clinical study titled "Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors". Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant i...
What is the current status of trial NCT06726148?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 280 participants. The study started on 2025-04-03. Estimated completion is 2028-09-25.
What conditions does trial NCT06726148 study?
This clinical trial studies the following conditions: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors.
What interventions are being tested in trial NCT06726148?
The interventions under investigation include: ribociclib (DRUG), fulvestrant (DRUG), ECI830 (DRUG).
Who is sponsoring clinical trial NCT06726148?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06726148 being conducted?
This trial has 20 study locations across California, Florida, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced HR+/HER2- Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Advanced HR+/HER2- Breast Cancer
All registered trials for this condition
Advanced CCNE1-amplified Solid Tumors
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.